RU2434630C2 - Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств - Google Patents

Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств Download PDF

Info

Publication number
RU2434630C2
RU2434630C2 RU2009111588/15A RU2009111588A RU2434630C2 RU 2434630 C2 RU2434630 C2 RU 2434630C2 RU 2009111588/15 A RU2009111588/15 A RU 2009111588/15A RU 2009111588 A RU2009111588 A RU 2009111588A RU 2434630 C2 RU2434630 C2 RU 2434630C2
Authority
RU
Russia
Prior art keywords
rviv
granules
coating
polymer
active pharmaceutical
Prior art date
Application number
RU2009111588/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009111588A (ru
Inventor
Гопи ВЕНКАТЕШ (US)
Гопи ВЕНКАТЕШ
Луиджи БОЛТРИ (US)
Луиджи Болтри
Итало КОЛОМБО (US)
Итало КОЛОМБО
Дзин-ванг ЛАИ (US)
Дзин-ванг ЛАИ
Флавио ФЛАБИАНИ (US)
Флавио ФЛАБИАНИ
Луиджи МАПЕЛЛИ (US)
Луиджи Мапелли
Original Assignee
Юранд, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юранд, Инк. filed Critical Юранд, Инк.
Publication of RU2009111588A publication Critical patent/RU2009111588A/ru
Application granted granted Critical
Publication of RU2434630C2 publication Critical patent/RU2434630C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009111588/15A 2006-08-31 2007-08-29 Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств RU2434630C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84189306P 2006-08-31 2006-08-31
US84176006P 2006-08-31 2006-08-31
US60/841,893 2006-08-31
US60/841,760 2006-08-31

Publications (2)

Publication Number Publication Date
RU2009111588A RU2009111588A (ru) 2010-10-10
RU2434630C2 true RU2434630C2 (ru) 2011-11-27

Family

ID=39136847

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009111588/15A RU2434630C2 (ru) 2006-08-31 2007-08-29 Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств

Country Status (12)

Country Link
US (3) US20080069878A1 (enExample)
EP (1) EP2056792B1 (enExample)
JP (2) JP5513113B2 (enExample)
KR (2) KR101468053B1 (enExample)
BR (1) BRPI0716196A2 (enExample)
CA (1) CA2661683C (enExample)
ES (1) ES2953390T3 (enExample)
IL (1) IL197204A0 (enExample)
MX (2) MX2009002166A (enExample)
NZ (1) NZ575171A (enExample)
RU (1) RU2434630C2 (enExample)
WO (1) WO2008027993A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2589701C1 (ru) * 2012-09-19 2016-07-10 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция для перорального введения с улучшенными растворимостью и/или всасываемостью

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
CA2711475A1 (en) * 2008-01-10 2009-07-16 Evonik Roehm Gmbh Coated pharmaceutical or nutraceutical preparation with accelerated controlled active substance release
ES2715274T3 (es) * 2008-01-10 2019-06-03 Evonik Roehm Gmbh Preparación farmacéutica o nutracéutica recubierta con liberación de sustancias activas mejorada
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
MX2010011880A (es) * 2008-04-29 2011-05-25 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular.
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
CA2722905C (en) * 2008-05-08 2016-08-16 Supernus Pharmaceuticals Inc. Controlled release formulations of alprazolam
FR2938432B1 (fr) * 2008-11-14 2011-05-20 Debregeas Et Associes Pharma Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus
KR101788804B1 (ko) * 2008-11-18 2017-10-20 유씨비 파마, 에스.에이. ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 지연 방출형 제형
MX339136B (es) * 2008-12-12 2016-05-13 Rhein Siegfried Sa De Cv Composicion de liberacion pulsatil de sildenafil y proceso para prepararla.
JP5783908B2 (ja) 2008-12-19 2015-09-24 スパーナス ファーマシューティカルズ インコーポレイテッド 攻撃性を治療する方法
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
KR101640164B1 (ko) * 2009-01-29 2016-07-15 유씨비 파마, 에스.에이. ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
JP2012518655A (ja) * 2009-02-23 2012-08-16 アプタリス ファーマテック インコーポレイテッド プロトンポンプ阻害剤を含む制御放出組成物
US20110311626A1 (en) * 2009-02-23 2011-12-22 Gopi Venkatesh Controlled release compositions comprising anti-cholinergic drugs
WO2010118232A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Controlled-release clozapine compositions
JP5758899B2 (ja) * 2009-09-17 2015-08-05 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 活性物質を含有するコーティングにより被覆されたペレット
FR2951378B1 (fr) * 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
MX337603B (es) 2009-11-30 2016-03-10 Adare Pharmaceuticals Inc Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion.
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
EP2515863A2 (en) 2009-12-23 2012-10-31 Lupin Limited Slow release pharmaceutical compositions of iloperidone
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2011082426A1 (en) * 2010-01-04 2011-07-07 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP3572074B1 (en) * 2010-03-31 2021-01-06 Supernus Pharmaceuticals, Inc. Stabilized formulations of molindone
EP2563339A1 (en) * 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
AU2011256928A1 (en) * 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
CA2804504C (en) * 2010-07-09 2018-08-21 Teijin Pharma Limited Intraorally disintegrating tablet
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CN102440971A (zh) * 2010-10-15 2012-05-09 重庆市力扬医药开发有限公司 伊潘立酮口腔崩解片
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
CN102614140B (zh) * 2011-01-26 2015-11-25 浙江九洲药物科技有限公司 伊潘立酮口崩片及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
KR20140057604A (ko) 2011-08-12 2014-05-13 베링거잉겔하임베트메디카게엠베하 고양잇과 동물의 심부전을 치료 및 예방하는 방법에 사용하기 위한 퍼니 전류 억제제
EP2604256B1 (en) * 2011-12-14 2016-04-13 Hexal AG Multi layer coatings
EP2704689B1 (en) * 2012-04-19 2018-11-28 Glatt AG Taste-masked pharmaceutical compositions containing diclofenac
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US9597339B2 (en) 2013-02-01 2017-03-21 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
WO2014144512A1 (en) 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015141662A1 (ja) * 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
JP2017528431A (ja) * 2014-07-17 2017-09-28 ジェローム シェンターク， 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11395808B2 (en) 2016-04-08 2022-07-26 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018055615A1 (en) * 2016-09-22 2018-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Injectable implants
WO2018156585A1 (en) * 2017-02-21 2018-08-30 Ico Therapeutics Inc. Solid oral formulations of amphotericin b
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CA3129056A1 (en) * 2018-02-21 2019-08-29 Aron H. BLAESI Expanding structured dosage form
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020061308A1 (en) * 2018-09-21 2020-03-26 Kashiv Biosciences, Llc Extended release compositions comprising trihexyphenidyl
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
US10679018B1 (en) 2019-02-05 2020-06-09 International Business Machines Corporation Magnetic tracking for medicine management
US10824822B2 (en) * 2019-02-05 2020-11-03 International Business Machines Corporation Magnetic tracking for medicine management
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) * 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN113350309B (zh) * 2021-08-09 2021-11-12 北京五和博澳药业股份有限公司 一种难溶性药物渗透泵控释片剂及其制备方法
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine
US12303604B1 (en) * 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057199A1 (en) * 2004-09-13 2006-03-16 Venkatesh Gopi M Orally disintegrating tablets of atomoxetine
US20060073200A1 (en) * 2004-10-05 2006-04-06 Recordati Ireland Limited Lercanidipine capsules

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
WO1991006291A1 (fr) * 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Preparation a liberation entretenue
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH08208476A (ja) * 1995-02-01 1996-08-13 Kanebo Ltd ニフェジピン含有持続性製剤
PT914818E (pt) 1996-06-14 2005-08-31 Kyowa Hakko Kogyo Kk Comprimido de desintegracao rapida por via intraoral
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
JP2000191519A (ja) * 1998-12-25 2000-07-11 Nippon Kayaku Co Ltd 薬効成分の不快な官能的性質が隠蔽された速放性粒状物
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP5062871B2 (ja) * 2003-05-13 2012-10-31 東和薬品株式会社 苦味を低減した口腔内崩壊錠剤
EP1694305B1 (en) * 2003-12-01 2019-10-16 Recordati Ireland Limited Pharmaceutical compositions comprising lercanidipine
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
GB0419355D0 (en) 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
NZ575171A (en) 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057199A1 (en) * 2004-09-13 2006-03-16 Venkatesh Gopi M Orally disintegrating tablets of atomoxetine
US20060073200A1 (en) * 2004-10-05 2006-04-06 Recordati Ireland Limited Lercanidipine capsules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Промышленная технология лекарств под ред. проф. В.И.Чуешова. - Харьков, 2002, т.2, с.383-392, (Глава 15). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2589701C1 (ru) * 2012-09-19 2016-07-10 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция для перорального введения с улучшенными растворимостью и/или всасываемостью

Also Published As

Publication number Publication date
US20210046015A1 (en) 2021-02-18
US12151028B2 (en) 2024-11-26
EP2056792A2 (en) 2009-05-13
EP2056792B1 (en) 2023-06-07
US10864166B2 (en) 2020-12-15
CA2661683A1 (en) 2008-03-06
EP2056792A4 (en) 2013-04-24
CA2661683C (en) 2015-11-24
IL197204A0 (en) 2009-12-24
ES2953390T3 (es) 2023-11-10
WO2008027993A2 (en) 2008-03-06
JP2013199488A (ja) 2013-10-03
WO2008027993A3 (en) 2008-09-12
US20140050797A1 (en) 2014-02-20
US20080069878A1 (en) 2008-03-20
KR20090057410A (ko) 2009-06-05
NZ575171A (en) 2012-04-27
MX370905B (es) 2020-01-09
RU2009111588A (ru) 2010-10-10
JP2010502645A (ja) 2010-01-28
JP5913207B2 (ja) 2016-04-27
JP5513113B2 (ja) 2014-06-04
MX2009002166A (es) 2009-03-12
KR20140114887A (ko) 2014-09-29
KR101468053B1 (ko) 2014-12-02
AU2007289235A1 (en) 2008-03-06
BRPI0716196A2 (pt) 2013-11-12

Similar Documents

Publication Publication Date Title
US12151028B2 (en) Drug delivery systems comprising solid solutions of weakly basic drugs
RU2524638C2 (ru) Орально распадающиеся таблеточные композиции темазепама
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
US20120093938A1 (en) Orally disintegrating tablets comprising diphenhydramine
US20110212171A1 (en) Taste masked topiramate composition and an orally disintegrating tablet comprising the same
RU2325163C2 (ru) Композиции с пролонгированным высвобождением, включающие ламотригин
TW201006509A (en) Compositions comprising weakly basic drugs and controlled-release dosage forms
US20090263478A1 (en) Carvedilol forms, compositions, and methods of preparation thereof
WO2011082426A1 (en) Controlled release compositions comprising meclizine or related piperazine derivatives
CN101553211B (zh) 包含弱碱性药物固溶体的药物递送系统
AU2007289235B2 (en) Drug delivery systems comprising solid solutions of weakly basic drugs
MX2009002267A (es) Procedimiento e intermediarios para la sintesis de derivados e intermediarios de (3-alquil-5-piperidin-1-il-3,3a-dihidro-pirazolo [1,5-a]pirimidin-7-il)-amino.
HK1148696A (en) Orally disintegrating tablet compositions of temazepam
HK1152201A (en) Orally disintegrating tablets comprising diphenhydramine

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160830